Cargando…

Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines

BACKGROUND: The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact recommendations. The objective of this project was to adapt a set of prioritized...

Descripción completa

Detalles Bibliográficos
Autores principales: Omair, Mohammed A., Al Rayes, Hanan, Khabsa, Joanne, Yaacoub, Sally, Abdulaziz, Sultana, Al Janobi, Ghada A., Al Khalaf, Abdulaziz, Al Mehmadi, Bader, Al Nassar, Mahasin, AlBalawi, Faisal, AlFurayj, Abdullah S., Al-Jedai, Ahmed Hamdan, Almalag, Haya Mohammed, Almudaiheem, Hajer Yousef, AlRehaily, Ali, Attar, Mohammed A., El Kibbi, Lina, Halabi, Hussein, Hasan, Manal, Singh, Jasvinder A., Fraenkel, Liana, Akl, Elie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682746/
https://www.ncbi.nlm.nih.gov/pubmed/36414983
http://dx.doi.org/10.1186/s41927-022-00301-y
_version_ 1784834920795865088
author Omair, Mohammed A.
Al Rayes, Hanan
Khabsa, Joanne
Yaacoub, Sally
Abdulaziz, Sultana
Al Janobi, Ghada A.
Al Khalaf, Abdulaziz
Al Mehmadi, Bader
Al Nassar, Mahasin
AlBalawi, Faisal
AlFurayj, Abdullah S.
Al-Jedai, Ahmed Hamdan
Almalag, Haya Mohammed
Almudaiheem, Hajer Yousef
AlRehaily, Ali
Attar, Mohammed A.
El Kibbi, Lina
Halabi, Hussein
Hasan, Manal
Singh, Jasvinder A.
Fraenkel, Liana
Akl, Elie A.
author_facet Omair, Mohammed A.
Al Rayes, Hanan
Khabsa, Joanne
Yaacoub, Sally
Abdulaziz, Sultana
Al Janobi, Ghada A.
Al Khalaf, Abdulaziz
Al Mehmadi, Bader
Al Nassar, Mahasin
AlBalawi, Faisal
AlFurayj, Abdullah S.
Al-Jedai, Ahmed Hamdan
Almalag, Haya Mohammed
Almudaiheem, Hajer Yousef
AlRehaily, Ali
Attar, Mohammed A.
El Kibbi, Lina
Halabi, Hussein
Hasan, Manal
Singh, Jasvinder A.
Fraenkel, Liana
Akl, Elie A.
author_sort Omair, Mohammed A.
collection PubMed
description BACKGROUND: The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact recommendations. The objective of this project was to adapt a set of prioritized recommendations from the 2021 ACR guideline for the treatment of rheumatoid arthritis RA for the context of Saudi Arabia, by the Saudi Society for Rheumatology (SSR). METHODS: The process followed the GRADE-ADOLOPMENT methodology, and the reporting adhered to the RIGHT-Ad@pt checklist. Working groups included a coordination group and a 19-member panel representing different stakeholder groups. The Evidence to Decision (EtD) tables included evidence on health effects from the source guideline and contextual information from the Saudi setting. RESULTS: The panel prioritized and adapted five recommendations from the source guideline. The process led to modifying two out of the five prioritized recommendations, all listed here. In naive patients with low disease activity, methotrexate (MTX) is conditionally recommended over sulfasalazine (SSZ) (modified direction); hydroxychloroquine (HCQ) is conditionally recommended over SSZ (unmodified). Initiation of csDMARDs with short-term glucocorticoids is conditionally recommended over csDMARDs alone in naive patients with moderate to high disease activity (modified direction). Switch to subcutaneous MTX is conditionally recommended over addition/switch to alternative DMARD(s) in patients taking oral MTX who are not at target (unmodified). Discontinuation of MTX is conditionally recommended over gradual discontinuation of the bDMARD or tsDMARD for patients taking MTX plus a bDMARD or tsDMARD who wish to discontinue a DMARD (unmodified). CONCLUSION: Rheumatologists practicing in Saudi Arabia can use the adoloped recommendations generated by this project while adopting the rest of the recommendations from the 2021 ACR guidelines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-022-00301-y.
format Online
Article
Text
id pubmed-9682746
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96827462022-11-24 Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines Omair, Mohammed A. Al Rayes, Hanan Khabsa, Joanne Yaacoub, Sally Abdulaziz, Sultana Al Janobi, Ghada A. Al Khalaf, Abdulaziz Al Mehmadi, Bader Al Nassar, Mahasin AlBalawi, Faisal AlFurayj, Abdullah S. Al-Jedai, Ahmed Hamdan Almalag, Haya Mohammed Almudaiheem, Hajer Yousef AlRehaily, Ali Attar, Mohammed A. El Kibbi, Lina Halabi, Hussein Hasan, Manal Singh, Jasvinder A. Fraenkel, Liana Akl, Elie A. BMC Rheumatol Research BACKGROUND: The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact recommendations. The objective of this project was to adapt a set of prioritized recommendations from the 2021 ACR guideline for the treatment of rheumatoid arthritis RA for the context of Saudi Arabia, by the Saudi Society for Rheumatology (SSR). METHODS: The process followed the GRADE-ADOLOPMENT methodology, and the reporting adhered to the RIGHT-Ad@pt checklist. Working groups included a coordination group and a 19-member panel representing different stakeholder groups. The Evidence to Decision (EtD) tables included evidence on health effects from the source guideline and contextual information from the Saudi setting. RESULTS: The panel prioritized and adapted five recommendations from the source guideline. The process led to modifying two out of the five prioritized recommendations, all listed here. In naive patients with low disease activity, methotrexate (MTX) is conditionally recommended over sulfasalazine (SSZ) (modified direction); hydroxychloroquine (HCQ) is conditionally recommended over SSZ (unmodified). Initiation of csDMARDs with short-term glucocorticoids is conditionally recommended over csDMARDs alone in naive patients with moderate to high disease activity (modified direction). Switch to subcutaneous MTX is conditionally recommended over addition/switch to alternative DMARD(s) in patients taking oral MTX who are not at target (unmodified). Discontinuation of MTX is conditionally recommended over gradual discontinuation of the bDMARD or tsDMARD for patients taking MTX plus a bDMARD or tsDMARD who wish to discontinue a DMARD (unmodified). CONCLUSION: Rheumatologists practicing in Saudi Arabia can use the adoloped recommendations generated by this project while adopting the rest of the recommendations from the 2021 ACR guidelines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-022-00301-y. BioMed Central 2022-11-23 /pmc/articles/PMC9682746/ /pubmed/36414983 http://dx.doi.org/10.1186/s41927-022-00301-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Omair, Mohammed A.
Al Rayes, Hanan
Khabsa, Joanne
Yaacoub, Sally
Abdulaziz, Sultana
Al Janobi, Ghada A.
Al Khalaf, Abdulaziz
Al Mehmadi, Bader
Al Nassar, Mahasin
AlBalawi, Faisal
AlFurayj, Abdullah S.
Al-Jedai, Ahmed Hamdan
Almalag, Haya Mohammed
Almudaiheem, Hajer Yousef
AlRehaily, Ali
Attar, Mohammed A.
El Kibbi, Lina
Halabi, Hussein
Hasan, Manal
Singh, Jasvinder A.
Fraenkel, Liana
Akl, Elie A.
Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
title Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
title_full Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
title_fullStr Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
title_full_unstemmed Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
title_short Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines
title_sort recommendations for the treatment of rheumatoid arthritis in saudi arabia: adolopment of the 2021 american college of rheumatology guidelines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682746/
https://www.ncbi.nlm.nih.gov/pubmed/36414983
http://dx.doi.org/10.1186/s41927-022-00301-y
work_keys_str_mv AT omairmohammeda recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT alrayeshanan recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT khabsajoanne recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT yaacoubsally recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT abdulazizsultana recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT aljanobighadaa recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT alkhalafabdulaziz recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT almehmadibader recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT alnassarmahasin recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT albalawifaisal recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT alfurayjabdullahs recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT aljedaiahmedhamdan recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT almalaghayamohammed recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT almudaiheemhajeryousef recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT alrehailyali recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT attarmohammeda recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT elkibbilina recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT halabihussein recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT hasanmanal recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT singhjasvindera recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT fraenkelliana recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines
AT akleliea recommendationsforthetreatmentofrheumatoidarthritisinsaudiarabiaadolopmentofthe2021americancollegeofrheumatologyguidelines